Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive disease and acute cardiovascular events. The pro-inflammatory cytokine, IL-1β is a central component of this inflammatory response and signalling is activated and amplified by the NLRP3 inflammasome. Rational therapeutic targeting of these mediators could modify atherosclerotic disease progression; myocardial remodelling and CAD patient outcomes. Here we discuss promising current and pipeline inhibitors of the NLRP3 inflammasome family.
|Number of pages||7|
|Journal||Online Journal of Cardiovascular Research|
|Early online date||13 Nov 2019|
|Publication status||Published - 13 Nov 2019|
McGilligan, V. E., Mcallister, R., Chemaly, M., Bjourson, AJ., & Peace, A. (2019). The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors. Online Journal of Cardiovascular Research, 2(3), 1.